J.P. Morgan Initiates Coverage on Sepracor (SEPR) with a Neutral
More News related to SEPR
- Matrix Lighthouse Rating Changes 11/28
- Results of Studies of ALVESCO(R) for the Treatment of Asthma and OMNARIS(TM) in an HFA Nasal Aerosol Presented at American College of Allergy, Asthma & Immunology Annual Meeting
- David Moenning's Daily State of the Markets: 10/28
- Sepracor (SEPR) Reports Mixed Q3 Earnings; Guides FY08
- Sepracor Inc. Reports 9.6% Increase in Revenue for Third Quarter and Tightens Range for Full-Year 2008 Financial Guidance
More News related to New Coverage
- Lumber Liquidators (LL) Founder/Chairman Sullivan Sold 282K Shares
- Zale (ZLC) Sees Heavy Insider Buying As Stock Hits New Low
- ION Geophysical (IO) Director Buys 50K Shares
- Sunstone Hotel Investors (SHO) CFO Buys 20K Shares
- Dillard's (DDS) Director White Buys 27K Shares
J.P. Morgan initiates coverage on Sepracor (Nasdaq: SEPR) with a Neutral rating.
Sepracor Inc. is a research-based pharmaceutical company engaged in the discovery, development and commercialization of differentiated products that are prescribed by primary care physicians and certain specialists.
Related Categories
New CoverageStocks Mentioned
-0.99Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
